Cochlear Limited Unveiled FY19 Results; Reported 7% Revenue Growth

Implantable hearing solutions provider, Cochlear Limited (ASX: COH) has reported a sales revenue growth of 7% in FY19. The company also earned a net profit (including the revaluation of innovation fund) of $276.7 million in FY19, an increase of 13% as compared to last year.

Sales Revenue Chart (Source: Company Reports)

Services revenue of the company increased by 20% over the period, with sound processor upgrade revenue increasing by 17%. Further, the cochlear implant business also witnessed a 2% growth in its revenue, but the total units declined by 3%. During the year, the company lost its market share in US and Germany due to a competitor product launch. However, both the markets have witnessed an uplift in sales since the launch of the Nucleus Profile Plus Series cochlear implant in Germany in mid-May and the US in late June.

In FY19, the operating cashflow of the company grew by $37.9 million to $296.0 million. The company’s Board has determined a final dividend of $1.75 cents per share, taking the full year dividends to $3.30 per share (fully franked) in FY19. It is to be noted that since listing, the company has cumulatively paid out around 70% of operating cash flows as dividends.

The company has a wide range of fully-featured products and a broad patent portfolio that protects the company’s intellectual property. Since listing, the company has invested more than $1.9 billion, with 13% of sales revenue invested in R&D in FY19.

Cochlear R&D Investment (Source: Company Reports)

By looking at Cochlear’s financial history, it is observed that there is a strong and consistent correlation between reported net profit and the operating cash flows generated by the business.

Correlation between reported net profit and the operating cash flows (Source: Company Reports)

Outlook

In the financial year 2020, the company is expecting its net profit to be in the range of $290 million to $300 million, representing an increase of 9-13% on FY19 underlying net profit. During FY19, the company was committed to making investment in market awareness and access activities. In late FY19, the company launched a number of new products, due to which it now expects strong growth in cochlear implant units.

In FY2020, the company will maintain its focus on growing the hearing implant market. The company believes that it is in a strong financial position, which is enabling it to fund its growth activities while rewarding shareholders along the way with a growing dividend stream.

In FY2020, the company is expecting to release the new osseointegrated steady-state implant (OSIA) product. The capital expenditure in FY2020 is expected to increase to around $180 million, including the continued development of the China manufacturing facility, fitout of the new, larger Denver office and investment in IT platforms to strengthen the company’s connected health, digital and cyber security capabilities. Later in FY21, the company expects its capital expenditure to drop to around $100 million.

The company is committed to building grass roots awareness with candidates through its direct-to consumer marketing activities. It is focussed on building referrals from the hearing aid channel in the US through the establishment of the Cochlear Provider Network, which links surgeons with hearing aid clinics, while building professional awareness through improved education.

CI532 MultiCenter Clinical Study (532) Study

During the year, the company received positive results from its ‘CI532 MultiCenter Clinical Study (532), a study which is designed to measure the benefits of bimodal cochlear implantation. This study found that, on average, participants achieved a 10-fold improvement in satisfaction with their hearing performance with cochlear implants over hearing aids, with dramatic improvements in the ability to understand conversations, hear on the phone and listen to and appreciate music, an encouraging news for the company and its shareholders.

The study is demonstrating the impact which implant has on the patient’s quality of life, an increasingly vital component of determining the value of funded interventions to payers. In addition, the study is also providing an important foundation for educating hearing professionals of the benefits of cochlear implants over hearing aids in this patient population.

Cochlear implants Performance

In the past 30 years, cochlear implants have been established as the standard of care for children born with a severe to profound hearing loss, with high adoption rates across most developed countries. One of the drivers of market growth for cochlear implants is the expansion of indications for funded implants. There are many countries that have either restrictive clinical indications or capped funding which limits access. The company is focussed on building its market access capability globally to advocate for the expansion of both indications and funding for cochlear implants.

In the last decade, there has been a greater uptake of cochlear implantation by older adults, particularly seniors, as awareness of the intervention has grown, and the body of evidence builds connecting good hearing with healthy ageing. With the growing awareness of cochlear implants, the funding is also expanding in emerging markets.

In the last few years, the company has launched market-leading products including:

  • Nucleus® Profile™ Plus Series cochlear implant, the world’s thinnest implant, designed for routine 1.5 and 3 Tesla magnetic resonance imaging scans without the need to remove the internal magnet;
  • Nucleus® 7 Sound Processor, the industry’s smallest and lightest behind-the-ear cochlear implant sound processor, enabling recipients to connect to compatible Apple® and Android devices;
  • Nucleus Kanso® Sound Processor, the company’s first off-the-ear sound processor;
  • Nucleus Profile Slim Modiolar (CI532) electrode, the world’s thinnest, full length perimodiolar electrode array designed to sit closest to the hearing nerve for optimal hearing outcomes; and
  • Baha® SoundArc, providing a non-surgical bone conduction solution that works together with all of Cochlear’s Baha 5 sound processors.

Market Opportunity

As per World Health Organization (WHO), more than 460 million people (5%) of the world’s population is currently experiencing disabling hearing loss. WHO expects these numbers to pump up to over 900 million people by 2050. This means that there is a significant, unmet and addressable clinical need which can be met through Cochlear products.

The company has estimated that over 15 million people could benefit from a cochlear or bone conduction implant to treat moderate to profound hearing loss across its target segments of children globally and adults and seniors in the developed world. The company believes that there is an opportunity to strengthen the treatment pathway for acquired or progressive hearing loss in older children.

Driving Growth

Cochlear has three programs for driving growth of the adults and seniors segment which include:

  • Direct-to-consumer marketing – continuing to expand the company’s successful direct-to-consumer (DTC) marketing activities;
  • Hearing aid channel referrals – building referrals from the hearing aid and ENT channels;
  • Standard of care initiatives – supporting initiatives to deliver a consistent treatment pathway for adults with severe to profound hearing loss.

Over the years, the company has increased its investment in health economics, its market access capability and the collaborations it has with the medical research community to build on the clinical evidence that demonstrates the effectiveness of its products, particularly for seniors.

The company has assured that it will continue to invest operating cash flows in market growth activities with the objective of delivering consistent revenue and earnings growth over the long term. Via disciplined investment, the company is targeting to maintain the net profit margin, reinvesting any efficiency gains, currency or tax benefits into market growth activities

Stock Performance

In the past six months, COH’s stock has provided a return of 3.23% as on 14 August 2019. COH’s stock is trading at a PE multiple of 44.030x with an annual dividend yield of 1.56%. At market close on 16th August 2019, COH’s stock was trading at a price of $209.500, up by 3.96% intraday, with a market capitalisation of circa $11.63 billion. The stock has a 52 weeks high price of $226.710 and 52 weeks low price of $155.220 with an average volume of ~165,690.


Disclaimer

This website is a service of Kalkine Media Pty. Ltd. A.C.N. 629 651 672. The website has been prepared for informational purposes only and is not intended to be used as a complete source of information on any particular company. Kalkine Media does not in any way endorse or recommend individuals, products or services that may be discussed on this site. Our publications are NOT a solicitation or recommendation to buy, sell or hold. We are neither licensed nor qualified to provide investment advice.

Join Our Discussion

Start discussion with value Investors for ASX Stock Market Investment and Opinion.


6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report